These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 39201382)

  • 1. Studying Pathogenetic Contribution of a Variant of Unknown Significance, p.M659I (c.1977G > A) in MYH7, to the Development of Hypertrophic Cardiomyopathy Using CRISPR/Cas9-Engineered Isogenic Induced Pluripotent Stem Cells.
    Pavlova SV; Shulgina AE; Zakian SM; Dementyeva EV
    Int J Mol Sci; 2024 Aug; 25(16):. PubMed ID: 39201382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced myofilament calcium sensitivity aggravates abnormal calcium handling and diastolic dysfunction in patient-specific induced pluripotent stem cell-derived cardiomyocytes with MYH7 mutation.
    Guo G; Wang L; Li X; Fu W; Cao J; Zhang J; Liu Y; Liu M; Wang M; Zhao G; Zhao X; Zhou Y; Niu S; Liu G; Zhang Y; Dong J; Tao H; Zhao X
    Cell Calcium; 2024 Jan; 117():102822. PubMed ID: 38101154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation of iPSC line from MYH7 R403L mutation carrier with severe hypertrophic cardiomyopathy and isogenic CRISPR/Cas9 corrected control.
    Fontaine V; Duboscq-Bidot L; Jouve C; Hamlin M; Curjol A; Briand V; Janiak P; Hulot JS; Pruniaux-Harnist MP; Charron P; Villard E
    Stem Cell Res; 2021 Apr; 52():102245. PubMed ID: 33610018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determining the Pathogenicity of a Genomic Variant of Uncertain Significance Using CRISPR/Cas9 and Human-Induced Pluripotent Stem Cells.
    Ma N; Zhang JZ; Itzhaki I; Zhang SL; Chen H; Haddad F; Kitani T; Wilson KD; Tian L; Shrestha R; Wu H; Lam CK; Sayed N; Wu JC
    Circulation; 2018 Dec; 138(23):2666-2681. PubMed ID: 29914921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isogenic models of hypertrophic cardiomyopathy unveil differential phenotypes and mechanism-driven therapeutics.
    Bhagwan JR; Mosqueira D; Chairez-Cantu K; Mannhardt I; Bodbin SE; Bakar M; Smith JGW; Denning C
    J Mol Cell Cardiol; 2020 Aug; 145():43-53. PubMed ID: 32531470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myosin inhibitor reverses hypertrophic cardiomyopathy in genotypically diverse pediatric iPSC-cardiomyocytes to mirror variant correction.
    Kinnear C; Said A; Meng G; Zhao Y; Wang EY; Rafatian N; Parmar N; Wei W; Billia F; Simmons CA; Radisic M; Ellis J; Mital S
    Cell Rep Med; 2024 May; 5(5):101520. PubMed ID: 38642550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation of two clonal iPSC lines, ICGi019-A and ICGi019-B, by reprogramming peripheral blood mononuclear cells of a patient suffering from hypertrophic cardiomyopathy and carrying a heterozygous p.M659I mutation in MYH7.
    Dementyeva EV; Kovalenko VR; Zhiven MK; Ustyantseva EI; Kretov EI; Vyatkin YV; Zakian SM
    Stem Cell Res; 2020 Jul; 46():101840. PubMed ID: 32422568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modelling diastolic dysfunction in induced pluripotent stem cell-derived cardiomyocytes from hypertrophic cardiomyopathy patients.
    Wu H; Yang H; Rhee JW; Zhang JZ; Lam CK; Sallam K; Chang ACY; Ma N; Lee J; Zhang H; Blau HM; Bers DM; Wu JC
    Eur Heart J; 2019 Dec; 40(45):3685-3695. PubMed ID: 31219556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allele-Specific Suppression of Variant MHC With High-Precision RNA Nuclease CRISPR-Cas13d Prevents Hypertrophic Cardiomyopathy.
    Yang P; Lou Y; Geng Z; Guo Z; Wu S; Li Y; Song K; Shi T; Zhang S; Xiong J; Chen AF; Li D; Pu WT; Da L; Zhang Y; Sun K; Zhang B
    Circulation; 2024 Jul; 150(4):283-298. PubMed ID: 38752340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation of induced pluripotent stem cells (iPSCs) from a hypertrophic cardiomyopathy patient with the pathogenic variant p.Val698Ala in beta-myosin heavy chain (MYH7) gene.
    Ross SB; Fraser ST; Nowak N; Semsarian C
    Stem Cell Res; 2017 Apr; 20():88-90. PubMed ID: 28395747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiomyocyte Apoptosis Is Associated with Contractile Dysfunction in Stem Cell Model of
    Loiben AM; Chien WM; Friedman CE; Chao LS; Weber G; Goldstein A; Sniadecki NJ; Murry CE; Yang KC
    Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generation of three induced pluripotent stem cell lines from hypertrophic cardiomyopathy patients carrying MYH7 mutations.
    Cao X; Jahng JWS; Lee C; Zha Y; Wheeler MT; Sallam K; Wu JC
    Stem Cell Res; 2021 Aug; 55():102455. PubMed ID: 34352619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CRISPR/Cas9 gene editing in induced pluripotent stem cells to investigate the feline hypertrophic cardiomyopathy causing MYBPC3/R820W mutation.
    Dutton LC; Dudhia J; Guest DJ; Connolly DJ
    PLoS One; 2024; 19(10):e0311761. PubMed ID: 39388496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiplexed Functional Assessments of
    Friedman CE; Fayer S; Pendyala S; Chien WM; Loiben A; Tran L; Chao LS; McKinstry A; Ahmed D; Farris SD; Stempien-Otero A; Jonlin EC; Murry CE; Starita LM; Fowler DM; Yang KC
    Circ Genom Precis Med; 2024 Apr; 17(2):e004377. PubMed ID: 38362799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incomplete-penetrant hypertrophic cardiomyopathy
    Lee S; Vander Roest AS; Blair CA; Kao K; Bremner SB; Childers MC; Pathak D; Heinrich P; Lee D; Chirikian O; Mohran SE; Roberts B; Smith JE; Jahng JW; Paik DT; Wu JC; Gunawardane RN; Ruppel KM; Mack DL; Pruitt BL; Regnier M; Wu SM; Spudich JA; Bernstein D
    Proc Natl Acad Sci U S A; 2024 May; 121(19):e2318413121. PubMed ID: 38683993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. iPSC-Based Modeling of Variable Clinical Presentation in Hypertrophic Cardiomyopathy.
    Escribá R; Larrañaga-Moreira JM; Richaud-Patin Y; Pourchet L; Lazis I; Jiménez-Delgado S; Morillas-García A; Ortiz-Genga M; Ochoa JP; Carreras D; Pérez GJ; de la Pompa JL; Brugada R; Monserrat L; Barriales-Villa R; Raya A
    Circ Res; 2023 Jul; 133(2):108-119. PubMed ID: 37317833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibiting cardiac myeloperoxidase alleviates the relaxation defect in hypertrophic cardiomyocytes.
    Ramachandra CJA; Kp MMJ; Chua J; Hernandez-Resendiz S; Liehn EA; Knöll R; Gan LM; Michaëlsson E; Jonsson MKB; Ryden-Markinhuhta K; Bhat RV; Fritsche-Danielson R; Lin YH; Sadayappan S; Tang HC; Wong P; Shim W; Hausenloy DJ
    Cardiovasc Res; 2022 Jan; 118(2):517-530. PubMed ID: 33705529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation of a hiPSC line ZZUNEUi007-A from a patient with hypertrophic cardiomyopathy caused by mutation in MYH7.
    Li X; Liu Y; Liu F; Wang X; Liu M; Du W; Zhao J; Wang M; Hu L; Wang C; Fu W; Dong J; Zhao X
    Stem Cell Res; 2020 Mar; 43():101699. PubMed ID: 31931472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of an induced pluripotent stem cell line (ZJULLi003-A) from a hypertrophic cardiomyopathy patient carrying MYH7/c.4384G > A mutation.
    Zhou J; Sun Y; Wang H; Wang H; Guo F; Chen X; Gong T; Jiang C; Liang P
    Stem Cell Res; 2022 Oct; 64():102883. PubMed ID: 35944310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A heterozygous MYH7 (c. 2156G > A) mutant human induced pluripotent stem cell line (ZZUNEUi020-A) generated from a patient with hypertrophic cardiomyopathy.
    Li X; Fu W; Guo G; Liu M; Du W; Zhao J; Liu Y; Wang L; Dong J; Zhao X
    Stem Cell Res; 2021 Mar; 51():102158. PubMed ID: 33453578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.